Abstract
We used ultradeep sequencing to investigate the evolution of the frequency of CXCR4-using viruses in the peripheral blood mononuclear cells of 22 patients infected with both CCR5 and CXCR4-using viruses treated with the CCR5 antagonist maraviroc for 24 weeks and a stable antiviral therapy. The mean CXCR4-using virus frequency in peripheral blood mononuclear cells was 59% before maraviroc intensification and 52% after 24 weeks of effective treatment, indicating no selection by maraviroc.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / administration & dosage*
-
Cyclohexanes / administration & dosage*
-
Genotype
-
HIV / classification
-
HIV / genetics
-
HIV / isolation & purification
-
HIV / physiology*
-
HIV Infections / drug therapy*
-
HIV Infections / virology*
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Leukocytes, Mononuclear / virology
-
Maraviroc
-
Selection, Genetic*
-
Triazoles / administration & dosage*
-
Viral Tropism*
Substances
-
Anti-HIV Agents
-
Cyclohexanes
-
Triazoles
-
Maraviroc